{"type":"trials","record":{"id":41743,"source_id":"clinicaltrials-gov","external_id":"NCT02243878","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","brief_summary":"This study investigates the use of radiation to treat wet age-related macular degeneration (AMD). The radiation is delivered using a robotically controlled device that projects overlapping beams of radiation onto the macula, the part of the eye that is affected by wet AMD. Participants will be randomized to receive radiation (stereotactic radiotherapy) or simulated placebo treatment (sham control). They will be followed up regularly for two years, and then again at the end of three and four years for a safety visit. Participants will also receive injections of ranibizumab (Lucentis) into their eye if their wet AMD is active. Ranibizumab is the standard anti-VEGF agent that is used to treat wet AMD. The study aims to determine if stereotactic radiosurgery can maintain vision and reduce the need for such regular anti-VEGF injections.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"King's College Hospital NHS Trust","enrollment":411,"countries":["United Kingdom"],"start_date":"2014-12-01","completion_date":"2024-04-01","last_update_date":"2025-08-06","source_url":"https://clinicaltrials.gov/study/NCT02243878","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"STAR","age_range":"50 Years to 110 Years","comparator":null,"organization":"King's College Hospital NHS Trust","interventions":["Stereotactic radiotherapy (16 Gray or Sham)","0.5 mg ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of as required (prn) ranibizumab injections during the first 24 months — 24 months","Mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) at 24 months. — 24 months"],"design_description":"RANDOMIZED · SINGLE GROUP · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular (Wet) Age-related Macular Degeneration (AMD)","Stereotactic radiotherapy (16 Gray or Sham)","0.5 mg ranibizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02243878","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-12-01 to 2024-04-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 110 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.864Z","intervention":["Stereotactic radiotherapy (16 Gray or Sham)","0.5 mg ranibizumab"],"participants":411,"study_design":"RANDOMIZED · SINGLE GROUP · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of as required (prn) ranibizumab injections during the first 24 months — 24 months","Mean Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) at 24 months. — 24 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41743","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}